Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) rose 5.7% during trading on Monday . The company traded as high as $2.97 and last traded at $2.96. Approximately 161,850 shares were traded during trading, a decline of 80% from the average daily volume of 804,095 shares. The stock had previously closed at $2.80.

NAVB has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective (up previously from $6.00) on shares of Navidea Biopharmaceuticals in a research note on Monday, August 17th. Zacks Investment Research downgraded shares of Navidea Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 21st. Finally, Maxim Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of Navidea Biopharmaceuticals in a research note on Friday, August 14th.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.01. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.60 million.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in Navidea Biopharmaceuticals in the 2nd quarter worth approximately $69,000. HighTower Advisors LLC boosted its stake in shares of Navidea Biopharmaceuticals by 82.5% during the 2nd quarter. HighTower Advisors LLC now owns 27,540 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 12,450 shares during the last quarter. Bridgeway Capital Management Inc. purchased a new position in shares of Navidea Biopharmaceuticals during the 2nd quarter valued at approximately $246,000. Finally, OTA Financial Group L.P. purchased a new position in shares of Navidea Biopharmaceuticals during the 2nd quarter valued at approximately $258,000.

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Featured Article: What does a bar chart mean for investors?

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.